Get the Stockscreener App
0.7459
5.58%
-0.0441
After Hours:
.73
-0.0159
-2.13%
Pasithea Therapeutics Corp stock is traded at $0.7459, with a volume of 1.07M.
It is down -5.58% in the last 24 hours and down -9.04% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
See More
Previous Close:
$0.79
Open:
$0.7742
24h Volume:
1.07M
Relative Volume:
3.38
Market Cap:
$18.60M
Revenue:
-
Net Income/Loss:
$-20.43M
P/E Ratio:
-0.2091
EPS:
-3.5677
Net Cash Flow:
$-15.21M
1W Performance:
-2.62%
1M Performance:
-9.04%
6M Performance:
+3.20%
1Y Performance:
-43.49%
1-Day Range:
$0.6999
$0.7898
1-Week Range:
$0.685
$0.79
52-Week Range:
$0.281
$3.79
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.7459 | 19.70M | 0 | -20.43M | -15.21M | -3.5677 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Can Pasithea Therapeutics Corp grow without external funding2026 Momentum Check & Verified Short-Term Plans - baoquankhu1.vn
Should you buy the dip on Pasithea Therapeutics Corp2026 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Loss Report: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Wrap: Can Pasithea Therapeutics Corp grow without external funding2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Opaleye/James Silverman hold 2.49M shares of Pasithea (KTTA) in Schedule 13G - Stock Titan
Aug Opening: Whats the beta of Pasithea Therapeutics Corp stockTreasury Yields & Daily Chart Pattern Signals - baoquankhu1.vn
Buyback Watch: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Pasithea Therapeutics Corp reports results for the quarter ended December 31Earnings Summary - TradingView
KTTA Should I Buy - Intellectia AI
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - Sahm
Trade Report: Is Pasithea Therapeutics Corp stock influenced by commodity prices2026 Biggest Moves & Technical Entry and Exit Tips - baoquankhu1.vn
Pasithea receives FDA fast track status for NF1 drug candidate By Investing.com - Investing.com Australia
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity - Investing News Network
Pasithea receives FDA fast track status for NF1 drug candidate - Investing.com
Pasithea Therapeutics Announces Grant of Fast Track - GlobeNewswire
KTTA SEC FilingsPasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Signal Recap: Whats the beta of Pasithea Therapeutics Corp stockDividend Hike & Verified Entry Point Detection - baoquankhu1.vn
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea (NASDAQ: KTTA) highlights PAS-004 trials and NF1 focus - Stock Titan
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Reviewing Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) - Defense World
Can Pasithea Therapeutics Corp disrupt its industryMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
Highs Report: What is the long term forecast for Pasithea Therapeutics Corp stockQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Vericel (NASDAQ:VCEL) versus Pasithea Therapeutics (NASDAQ:KTTA) Critical Review - Defense World
Can Pasithea Therapeutics Corp sustain earnings growth2026 Chart Watch & High Yield Stock Recommendations - baoquankhu1.vn
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock - simplywall.st
Winners Losers: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly priced2026 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
Panic Selling: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockGDP Growth & Weekly High Momentum Picks - baoquankhu1.vn
Pasithea Therapeutics Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Layoff Watch: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Gains Report: Is Pasithea Therapeutics Corp Equity Warrant attractive for institutional investors2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Analyst Calls: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Momentum & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Aug EndMonth: What is Pasithea Therapeutics Corp Equity Warrants revenue forecast2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Monday - Defense World
Smart Money: Whats the beta of Pasithea Therapeutics Corp stock2026 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Pullback Watch: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly priced2026 Price Action Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Fund Flows: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising rates2026 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Will Pasithea Therapeutics Corp. Equity Warrant stock recover faster than market2026 Patterns & Entry Point Strategy Guides - Naître et grandir
RSI Check: What is Pasithea Therapeutics Corp Equity Warrants revenue forecastJuly 2025 Rallies & Expert Approved Momentum Ideas - baoquankhu1.vn
Earnings Recap: Whats the beta of Pasithea Therapeutics Corp stockMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Fed Watch: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Certain Options of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com
Certain Common Stock of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com
KTTA PE Ratio & Valuation, Is KTTA Overvalued - Intellectia AI
KTTA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Coastlands entities hold 2.39M shares in Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
KTTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
What’s next for Pasithea Therapeutics Corp. stockTrade Entry Report & AI Enhanced Execution Alerts - mfd.ru
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):